Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: "Of more than 300 men and women who had the surgery, a third stopped playing sports entirely and 68 who were still active said they didn’t play as well as before, researchers reported in the American Journal of Sports Medicine. The anterior cruciate ligament, or ACL, is the ligament inside the knee that helps keep the joint stable. About 150,000 ACL injuries occur each year in the United States. “Less than 50 percent of the study sample had returned to playing sport at their preinjury level or returned to participating in competitive sport when surveyed at 2 to 7 years after ACL reconstruction surgery,” wrote Clare Ardern at La Trobe University in Victoria, Australia, who led the study. Ardern and her colleagues followed more than 300 men and women for two to seven years. Participants had either played Australian-rules football, basketball, netball or soccer before their surgeries. At 39 months post-surgery, 208 out of the 314 people who had the operation were still playing a sport, the researchers said. Of those 208, 68 said they played at a lower level than before their injury and 140 said they played about the same as before their injury. The remaining 106 participants either were not playing sports or did not complete the entire study. “Although almost all people returned to playing some form of sport, they did not play continuously for many years after their surgery,” Ardern told Reuters Health in an email. She also noted there may be other reasons why people stopped playing sports, such as fear of getting injured again or less confidence in performing. Of the 196 people who played competitive sports before their injury, 91 returned to their competitive sport. “This is a big injury,” said Edward McDevitt, a spokesman for the American Academy of Orthopaedic Surgeons, who was not part of the study. “Many athletes who choose surgery have a long and difficult road to face. If you’re not willing to go through it, then you might be better off just getting a brace.”   He added that while knee surgery does allow people to return to their sport, they couldn’t perform as well as doctors might wish. People who tear the ACL can either opt for physical therapy and surgery or just physical therapy alone. “Some people find that they are able to function well without surgery, provided they have adequate leg strength to support the injured knee,” Ardern said. “Other alternatives may be to avoid sports involving direction changes, jumping and landing or activities that make the knee feel unstable, or use knee braces and supports.”   McDevitt speculates that after surgery, some athletes may not have the same range of motion, preventing them from playing as before. ""I tell my patients, 'I can't make you like before, I'm not God. But I'll do the best I can to restore you back to the way you were,'"" he added. SOURCE: bit.ly/pWId18" Claim: After knee repair, half can't play sports the same.
[A]: After knee reconstruction surgery, half of people who played sports both competitively and just for fun don’t perform as well as they used to, according to an Australian study.


[Q]: Paragraph: The lawsuit marks the first multi-plaintiff trial in the litigation over whether glyphosate, Roundup’s active ingredient, is carcinogenic, and is the first trial outside of California. It is being held in St. Louis, where Monsanto was headquartered before Bayer bought the company in a $63 billion deal in 2018. Three consecutive juries found the company liable for causing cancer with damages of tens of millions of dollars awarded to each plaintiff. Bayer is appealing those verdicts. Court-appointed mediator Ken Feinberg has put the number of Roundup cancer claimants at more than 75,000 while Bayer said the claims it has been served with in court were below 50,000. Bayer’s share price has tumbled since the first verdict in August 2018 but the stock rose 3% on Friday after Bloomberg reported a possible out-of-court settlement with some plaintiffs that could lead to a total payout of about $10 billion. While traders said the market likes the idea of Bayer settling the litigation, some cautioned that the prospect of a comprehensive deal remained uncertain. Analysts have estimated the size of any such settlement at $8-$12 billion. While most plaintiffs’ lawyers have agreed to postpone trials pending negotiations, some have decided to pursue their clients’ day in court. The case in Missouri’s Circuit Court for the 22nd Judicial Circuit of the City of St. Louis is scheduled to last several weeks, with both sides presenting extensive scientific evidence through expert witnesses. Bayer denies all allegations that Roundup or glyphosate causes cancer, saying decades of independent studies have shown the world’s most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product. “At the end of the day, this trial should come down to the weight of the science, and we remain confident in the extensive scientific record and regulatory assessments that support the safety of our glyphosate-based herbicides and that they do not cause cancer,” the company said in a statement. Several court cases have been postponed by both parties in the past to expedite settlement talks. By pursuing the St. Louis trail The Miller Firm LLC, a key player in the litigation, is seeking to increase pressure on Bayer. The case involves the claims of Bryce Batiste from Louisiana, Ann Meeks from Florida, Glen Ashelman from Pennsylvania and Christopher Wade, a St. Louis resident. All four have been diagnosed with non-Hodgkin’s lymphoma, a blood cell cancer that plaintiffs in the litigation allege is caused by Roundup. Some legal experts said Bayer could benefit from a home advantage in the St. Louis trial, where Monsanto has century-old roots. But juries in the city are also known to dole out massive damages awards against large corporations. Claim: Bayer faces fourth U.S. Roundup cancer trial in Monsanto's hometown.
[A]: Bayer AG is set to face a fourth U.S. jury trial over allegations that its Roundup weed killer causes cancer, with four cancer patients in the hometown of its agricultural subsidiary Monsanto scheduled to begin making their case on Friday.


[Q]: Paragraph: "TXA costs $10 per treatment, according to the story. Although this cost is characterized as low, the story could have noted that the price may be prohibitively expensive in many poor countries. The story focuses on mortality difference between the TXA and placebo groups and presents the results in absolute terms. It helpfully notes that TXA would need to be adminstered to 66 patients to prevent one death. Although it passes along the claim that TXA might save ""tens of thousands of people"" without questioning it, the story doesn’t hype the assertion quite as vigorously as the competing coverage. The story mentioned there was no increase in deaths due to blood clots in the TXA group. We understand it’s a blog brief – so this is sufficient. The story provides the bare essentials noting the outcomes in absolute numbers and in number needed to treat. Unfortunately, several important facts were not reported including the number of sites involved, the number of countries and other essential attributes of the study. Nonetheless, we’ll give it the benefit of the doubt. No disease-mongering in this story. It’s difficult to find room for an independent perspective in a 245-word brief, and this story didn’t find the room. Numerous other pro-coagulatory agents are used to help control bleeding in trauma patients. The story didn’t mention any of them. The story states that TXA is a 25-year-old medicine that is approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled. The story mentions that TXA is already used to control bleeding during surgery and doesn’t portray the treatment as new. While there’s no evidence that this story lifted anything directly from a news release, we can’t be sure to what extent this story may have relied on one. We’ll call it not applicable." Claim: Generic Drug Could Save Many Trauma Patients
[A]:
While it earns credit for presenting the benefits in absolute terms and for including the number-needed-treat to save a life, this was the only story of the three that failed to include an independent perspective on the results. A good effort considering the space limitations, but a few more caveats would have been appreciated. Even in a brief such as this, there needs to space for an independent take on the issue.